Loading stock data…
GILD
$132.69+1.04 (+0.79%)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $132.69. The stock is currently 16% below its 52-week high of $157.29, remaining 5.5% above its 200-day moving average. Technical signals show neutral RSI of 31 and bearish MACD signal, explaining why GILD maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 31) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$132.69
Potential Upside
20.2%
Whystock Fair Value$159.48
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$158.36+19.3%
Range$123.00 – $180.00
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$164.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Strong income play. Yield provides a meaningful total return floor.
247.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.80%
Volume
Today's trading volume
5.57M
Recent News
Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients
1 S&P 500 Stock to Own for Decades and 2 We Avoid
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story
FDA accepts Gilead Sciences' New Drug Application for a once-daily single-tablet HIV regimen combining bictegravir and lenacapavir, granting priority review with an expected decision by late August 2026. Phase 3 data for the regimen have shown encouraging efficacy and tolerability in people living with HIV. Gilead completes its acquisition of Arcellx, adding an investigational CAR T cell therapy for multiple myeloma to its pipeline. Gilead Sciences, NasdaqGS:GILD, is drawing attention as it...